Thymalin

Overview

Thymalin is part of the Khavinson peptide bioregulator system — a family of organ-specific peptide extracts developed at the St. Petersburg Institute of Bioregulation and Gerontology in Russia from the 1970s onward. The thymalin extract targets the thymus gland, which undergoes progressive involution (shrinkage and functional decline) starting in adolescence, with dramatic effects by middle age.

Thymic involution is recognized as a central mechanism of immunosenescence — the age-related decline in immune competence that contributes to increased infection susceptibility, cancer risk, and autoimmune phenomena in older adults. By the time a person reaches 65, the thymus may be largely replaced by fatty tissue, producing dramatically fewer naive T-cells.

Mechanism

Thymic Function Restoration

Thymalin contains a mixture of oligopeptides (typically <10 kDa) that collectively:

1. Stimulate thymocyte differentiation: Promote maturation of T-cell precursors into functional T-cell subsets
2. Thymic epithelial cell support: Restore function of thymic stromal cells that present self-antigens for T-cell education
3. NK cell activation: Increase natural killer cell activity and cytotoxicity
4. Cytokine balance restoration: Normalize IL-2, interferon-γ, and other T-cell cytokines that decline with age
5. Telomerase activation (proposed): Some Khavinson data suggests peptide bioregulators activate telomerase in target cells, slowing replicative aging

Khavinson Peptide Framework

Thymalin is one of several organ-specific bioregulators in the Khavinson system:

• Thymalin → thymus/immune system
• Epithalon → pineal gland/circadian rhythm/longevity
• Cortexin → cerebral cortex/neuroprotection
• Prostamax → prostate gland
• Cardiogen → heart
• Testagen → testes

Each is proposed to act as a "peptide signal" that restores the epigenetic and transcriptional program of its target organ toward a younger state.

Longitudinal Clinical Data

Khavinson's most cited study followed elderly patients (78–89 years) over 6 years with periodic thymalin and epithalon administration. Key findings:

• ~2.0-fold reduction in all-cause mortality vs. control group
• Improved immune markers (T-cell counts, NK activity)
• Better cardiovascular and metabolic parameters

While these studies have methodological limitations common to Eastern European clinical research of that era (limited blinding, small N), the consistency of findings across multiple Khavinson studies has attracted longevity research attention.